Q1 2026 Nanoform Finland Oyj Earnings Call Transcript
Key Points
- Nanoform Finland PLC (FRA:4YL) reported a record first-quarter revenue and gross margin, indicating strong financial performance.
- The company signed its first exclusivity deal for its biologics technology, marking a significant milestone and establishing a second bio platform.
- Nanoform's lead program, nanoenzalutamide, is progressing with a multi-track strategy, showing confidence from all involved parties.
- The company achieved a 45% average income growth over the last six years, with a gross margin of 94%, highlighting efficient operations.
- Nanoform is on track to meet its 2030 business targets, including having three products on the market and achieving an EBIT margin above 30%.
- Despite the strong start, there is uncertainty about achieving some near-term business targets, which have become harder to meet.
- The company is still in the process of reducing operating expenses, with full effects expected in the third quarter, indicating ongoing financial adjustments.
- Nanoform's biologics platform is not yet GMP-ready, and there is uncertainty about the timeline for achieving GMP status.
- The company relies on external partners for funding the GMP build-out for biologics, which could pose risks if partnerships do not materialize as expected.
- There is a need for additional spending on formulation work for nanoenzalutamide, which could impact cash flow, although it is not expected to be material.
Welcome to the conference call. (Operator Instructions)
Now I will hand the conference over to the speakers. Please go ahead.
Thank you, and good day all, and a warm welcome to Nanoform's first-quarter 2026 report presentation. My name is Henri von Haartman, and I'm your Director of Investor Relations. Today, our CEO, Edward Haeggstrom; CFO, Albert Haeggstrom; Chief Commercial Officer, Christian Jones; and Chief Development Officer, Peter Hanninen, will present to you.
This presentation is webcasted through investor call, and there is also the possibility to call in and listen by phone. The presentation slides are shown throughout the webcast and they can also be found on our web page in the Investors section. After the presentation, we will hold a Q&A and it's possible to ask questions by calling in. We will today start with a short introduction and key business highlights, then financials, then commercial, and we conclude with our product terminals and the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
